Jubilant Biosys is an API manufacturer based in India. It holds 182 active US drug master files. Its GMP standing is certified by MFDS (Korea). Its most recent recorded inspection, by US FDA, closed on 13 December 2022 as VAI. Customs aggregates show $15.9M of exports covering 1,072 molecules to 36 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Mysuru, India | 3003144728 |
| Molecule | Regulators | Docs |
|---|---|---|
| Esomeprazole | US FDA | 10 |
| Azithromycin | SFDA (Saudi Arabia), US FDA | 5 |
| Bupropion | US FDA | 4 |
| Citalopram | US FDA | 4 |
| Escitalopram | US FDA | 4 |
| Oxcarbazepine | US FDA | 4 |
| Paliperidone | US FDA | 4 |
| Rivastigmine | US FDA | 4 |
| Aprepitant | SFDA (Saudi Arabia), US FDA | 3 |
| Alendronic Acid | US FDA | 2 |
| Aliskiren | US FDA | 2 |
| Apixaban | US FDA | 2 |
| Apremilast | US FDA | 2 |
| Aripiprazole | US FDA | 2 |
| Atorvastatin | US FDA | 2 |
| Azilsartan Medoxomil | US FDA | 2 |
| Bosentan | US FDA | 2 |
| Brexpiprazole | US FDA | 2 |
| Carbamazepine | US FDA | 2 |
| Cetirizine | US FDA | 2 |
| Cinacalcet | US FDA | 2 |
| Clopidogrel | US FDA | 2 |
| Cyclobenzaprine | US FDA | 2 |
| Dabigatran Etexilate | US FDA | 2 |
| Darifenacin | US FDA | 2 |
| Deferasirox | US FDA | 2 |
| Dexlansoprazole | US FDA | 2 |
| Donepezil | US FDA | 2 |
| Duloxetine | US FDA | 2 |
| Entacapone | US FDA | 2 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MFDS (Korea) | None | 2 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $7.6M | 41 |
| 2025 | Not reported | $15.9M | 36 |
| 2024 | Not reported | $3.2M | 16 |
| 2023 | Not reported | $4.0M | 14 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Jubilant Biosys comes back tiered against every other supplier able to file there.
Start for free